Why GlaxoSmithKline plc Has Attractive Growth Prospects

A return to growth is on the cards for GlaxoSmithKline plc (LON: GSK).

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

GlaxoSmithKlineA forecast increase in earnings per share (EPS) of 0% for 2014 might not be the stuff that growth dreams are made of, especially after a mere 1% rise in 2013, but for GlaxoSmithKline (LSE: GSK) (NYSE: GSK.US) those two years could mark the turning point in the company’s return to steady EPS growth.

What cliff?

The ‘patent cliff’, with protection on some key drugs expiring and opening up the way to competition, has not had as bad an effect on GlaxoSmithKline as some had feared, and there’s an 8% rise in EPS forecast for the year to December 2015.

So what are the longer-term growth prospects for the pharmaceutical giant looking like?

Full-year results for 2013, released on 5 February, showed flat turnover, but the fourth quarter was actually picking up with a 5% rise at constant exchange rates — and the company told us that ‘core’ EPS, at 112.2p, was up 4%.

The dividend for the year was lifted 5% to 78p, representing a yield of 4.6% on the current share price of 1,682p — and added to share repurchases of £1.5bn, GlaxoSmithKline returned £5.2bn in cash to shareholders during the course of 2013.

R&D is the key

But the crucial thing for those seeking long-term growth is the company’s drugs development, and in a period described as an “exceptional year for R&D delivery“, we saw six major new products approved, with a further five further regulatory filings being made.

The new products cover pretty lucrative areas too, including respiratory conditions, vaccines, oncology and HIV treatments — and the firm’s range of respiratory products looks set for long-term growth, with two major approvals in the period and seven possibilities in late-stage development.

Pipeline

Overall, chief executive Sir Andrew Witty described 2013 as “the most productive period of R&D output in the Company’s history“, telling us of another “40 NMEs in Phase II/III clinical development” — and the firm has “Phase III data for 6 potential new drugs and vaccines and around 10 NME Phase III starts across 2014 and 2015“.

What all this tells me more than anything is that, in the pharmaceuticals world, big is best. And with patent expiry having been threatening profits, GlaxoSmithKline’s strategy of focusing on its key strengths, divesting itself of non-core business, and using its financial power to make promising acquisitions and pour cash into R&D to refill that pipeline — well, it’s really hard to compete against a steamroller like that.

A new growth phase?

So, a core EPS rise of 4% in 2013, a big focus on pipeline development in 2014 and beyond, and an 8% total EPS rise forecast for 2015 — we really could be looking at the start of a new phase of steady earnings growth.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

> Alan does not own any shares in GlaxoSmithKline. The Motley Fool has recommended shares in GlaxoSmithKline.

More on Investing Articles

Businessman use electronic pen writing rising colorful graph from 2023 to 2024 year of business planning and stock investment growth concept.
Investing Articles

Buying 8,617 Legal & General shares would give me a stunning income of £1,840 a year

Legal & General shares offer one of the highest dividend yields on the entire FTSE 100. Harvey Jones wants to…

Read more »

Man writing 'now' having crossed out 'later', 'tomorrow' and 'next week'
Investing Articles

£25k to invest? Here’s how I’d try to turn that into a second income of £12,578 a year!

If Harvey Jones had a lump sum to invest today he'd go flat out buying top FTSE 100 second income…

Read more »

Union Jack flag in a castle shaped sandcastle on a beautiful beach in brilliant sunshine
Investing Articles

2 lesser-known dividend stocks to consider this summer

Summer is here and global markets could be heading for a period of subdued trading. But our writer thinks there…

Read more »

pensive bearded business man sitting on chair looking out of the window
Investing Articles

Here’s how I’d aim to build a £50K SIPP into a £250K retirement fund

Our writer outlines the approach he would take to try and increase the value of his SIPP multiple times in…

Read more »

Investing Articles

9.4%+ yields! 3 proven FTSE 100 dividend payers I’d buy for my Stocks and Shares ISA

Our writer highlights a trio of FTSE 100 shares with yields close to 10%. He'd happily pop them into his…

Read more »

Mixed-race female couple enjoying themselves on a walk
Investing Articles

Are Raspberry Pi shares a once-in-a-lifetime chance to get rich?

With Raspberry Pi shares surging after a successful IPO, could this UK tech startup offer a long-term wealth creation opportunity…

Read more »

Newspaper and direction sign with investment options
Investing Articles

Huge gains and 9% yields: why now’s an amazing time to be a stock market investor

The stock market’s generating fantastic returns in 2024. Whether you're looking for gains or income, it’s a great time to…

Read more »

Hand of person putting wood cube block with word VALUE on wooden table
Investing Articles

This steady dividend payer looks like one of the best bargain stocks in the FTSE 100

A yield of 4.7% and a consistent dividend record make this FTSE 100 company look like good value in an…

Read more »